Skip to main content
Top
Published in: Supportive Care in Cancer 6/2018

Open Access 01-06-2018 | Original Article

Humanistic burden of disease for patients with advanced melanoma in Canada

Authors: Winson Y. Cheung, Martha S. Bayliss, Michelle K. White, Angela Stroupe, Andrew Lovley, Bellinda L. King-Kallimanis, Kathryn Lasch

Published in: Supportive Care in Cancer | Issue 6/2018

Login to get access

Abstract

Background

Metastatic melanoma is a highly aggressive cancer, often striking in the prime of life. This study provides new information directly from advanced melanoma (stage III and IV) patients on how their disease impacts their health-related quality of life (HRQL).

Methods

Twenty-nine in-depth, qualitative interviews were conducted with adult patients with advanced melanoma in Canada. A semi-structured interview guide was used. Interviews were transcribed verbatim and key concepts were identified using a grounded theory analytic approach.

Results

Many patients’ journeys began with the startling diagnosis of an invasive disease and a vastly shortened life expectancy. By the time they reached an advanced stage of melanoma, these patients’ overall functioning and quality of life had been greatly diminished by this quickly progressing cancer. The impact was described in terms of physical pain and disability, emotional distress, diminished interactions with friends and family, and burden on caregivers.

Conclusion

Our findings provide evidence of signs, symptoms, and functional impacts of advanced melanoma. Signs and symptoms reported (physical, mental, and social) confirm and expand on those reported in the existing clinical literature. Primary care physicians should be better trained to identify melanomas early. Oncology care teams can improve on their current approaches for helping patients navigate treatment options, with information about ancillary services to mitigate disease impacts on HRQL, such as mental health and social supports, as well as employment or financial support services.
Literature
1.
2.
go back to reference Canadian Cancer Society’s Advisory Committee on Cancer Statistics (2016) Canadian cancer statistics 2016. Canadian Cancer Society, Toronto Canadian Cancer Society’s Advisory Committee on Cancer Statistics (2016) Canadian cancer statistics 2016. Canadian Cancer Society, Toronto
4.
go back to reference Sandru A, Voinea S, Panaitescu E, Blidaru A (2014) Survival rates of patients with metastatic malignant melanoma. J Med Life 7(4):572–576PubMedPubMedCentral Sandru A, Voinea S, Panaitescu E, Blidaru A (2014) Survival rates of patients with metastatic malignant melanoma. J Med Life 7(4):572–576PubMedPubMedCentral
6.
go back to reference Greene MH (1999) The genetics of hereditary melanoma and nevi. 1998 update. Cancer 86(11 Suppl):2464–2477CrossRef Greene MH (1999) The genetics of hereditary melanoma and nevi. 1998 update. Cancer 86(11 Suppl):2464–2477CrossRef
7.
go back to reference Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC Jr, Morton DL, Ross MI, Sober AJ, Sondak VK (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27(36):6199–6206. https://doi.org/10.1200/JCO.2009.23.4799 CrossRef Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC Jr, Morton DL, Ross MI, Sober AJ, Sondak VK (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27(36):6199–6206. https://​doi.​org/​10.​1200/​JCO.​2009.​23.​4799 CrossRef
9.
go back to reference Dubravcic ID, Brozic JM, Aljinovic A, Sindik J (2014) Quality of life in Croatian metastatic melanoma patients. Coll Antropol 38(1):69–74PubMed Dubravcic ID, Brozic JM, Aljinovic A, Sindik J (2014) Quality of life in Croatian metastatic melanoma patients. Coll Antropol 38(1):69–74PubMed
11.
go back to reference Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, Gore M, Aamdal S, Cebon J, Coates A, Dreno B, Henz M, Schadendorf D, Kapp A, Weiss J, Fraass U, Statkevich P, Muller M, Thatcher N (2000) Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18(1):158–166. https://doi.org/10.1200/JCO.2000.18.1.158 CrossRefPubMed Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, Gore M, Aamdal S, Cebon J, Coates A, Dreno B, Henz M, Schadendorf D, Kapp A, Weiss J, Fraass U, Statkevich P, Muller M, Thatcher N (2000) Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18(1):158–166. https://​doi.​org/​10.​1200/​JCO.​2000.​18.​1.​158 CrossRefPubMed
12.
go back to reference Brandberg Y, Johansson H, Aamdal S, Bastholt L, Hernberg M, Stierner U, von der Maase H, Hansson J, for the Nordic Melanoma Cooperative Group (2013) Role functioning before start of adjuvant treatment was an independent prognostic factor for survival and time to failure. A report from the Nordic adjuvant interferon trial for patients with high-risk melanoma. Acta Oncol 52(6):1086–1093. https://doi.org/10.3109/0284186X.2013.789140 CrossRefPubMed Brandberg Y, Johansson H, Aamdal S, Bastholt L, Hernberg M, Stierner U, von der Maase H, Hansson J, for the Nordic Melanoma Cooperative Group (2013) Role functioning before start of adjuvant treatment was an independent prognostic factor for survival and time to failure. A report from the Nordic adjuvant interferon trial for patients with high-risk melanoma. Acta Oncol 52(6):1086–1093. https://​doi.​org/​10.​3109/​0284186X.​2013.​789140 CrossRefPubMed
15.
go back to reference Coates A, Thomson D, McLeod GR, Hersey P, Gill PG, Olver IN, Kefford R, Lowenthal RM, Beadle G, Walpole E (1993) Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma. Eur J Cancer 29A(12):1731–1734CrossRef Coates A, Thomson D, McLeod GR, Hersey P, Gill PG, Olver IN, Kefford R, Lowenthal RM, Beadle G, Walpole E (1993) Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma. Eur J Cancer 29A(12):1731–1734CrossRef
21.
go back to reference Strauss A, Corbin J (1998) Basics of qualitative research: techniques and procedures for developing grounded theory. Sage, London Strauss A, Corbin J (1998) Basics of qualitative research: techniques and procedures for developing grounded theory. Sage, London
24.
go back to reference Charmaz K (2000) Grounded theory: objectivist and constructivist methods. In: Denzin N, Lincoln Y (eds) Handbook of qualitative inquiry, 2nd edn. Sage, Thousand Oaks Charmaz K (2000) Grounded theory: objectivist and constructivist methods. In: Denzin N, Lincoln Y (eds) Handbook of qualitative inquiry, 2nd edn. Sage, Thousand Oaks
25.
go back to reference Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, Ring L (2011) Content validity—establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1—eliciting concepts for a new PRO instrument. Value Health 14(8):967–977. https://doi.org/10.1016/j.jval.2011.06.014 CrossRefPubMed Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, Ring L (2011) Content validity—establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1—eliciting concepts for a new PRO instrument. Value Health 14(8):967–977. https://​doi.​org/​10.​1016/​j.​jval.​2011.​06.​014 CrossRefPubMed
26.
go back to reference ATLAS.ti Scientific Software Development GmbH (2015) ATLAS.ti [computer software]. ATLAS.ti Scientific Software Development GmbH, Version 7.5.4. Berlin, Germany ATLAS.ti Scientific Software Development GmbH (2015) ATLAS.ti [computer software]. ATLAS.ti Scientific Software Development GmbH, Version 7.5.4. Berlin, Germany
Metadata
Title
Humanistic burden of disease for patients with advanced melanoma in Canada
Authors
Winson Y. Cheung
Martha S. Bayliss
Michelle K. White
Angela Stroupe
Andrew Lovley
Bellinda L. King-Kallimanis
Kathryn Lasch
Publication date
01-06-2018
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 6/2018
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-017-4025-9

Other articles of this Issue 6/2018

Supportive Care in Cancer 6/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine